TMPRSS2 and prostate carcinoma: In ~50% of prostate cancers a chromosomal rearrangement results in the fusion of the androgen-regulated promoter of TMPRSS2 to the open reading frame of ERG and results in aberrant expression of either full-length, or N-terminally truncated ERG protein in prostate epithelium [2].